We are live on ! Find out more
DP

Diadema Partners Portfolio holdings

AUM $588M
1-Year Est. Return 182.75%
This Fund
S&P 500
This Quarter Est. Return
+77.63%
1 Year Est. Return
+182.75%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$581M
AUM Growth
+$190M
Cap. Flow
+$101M
Cap. Flow %
17.32%
Top 10 Hldgs %
39.55%
Holding
201
New
71
Increased
49
Reduced
24
Closed
56

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$13.1M
2
CORT icon
Corcept Therapeutics
CORT
+$7.65M
3
VKTX icon
Viking Therapeutics
VKTX
+$5.07M
4
UTHR icon
United Therapeutics
UTHR
+$4.66M
5
BBIO icon
BridgeBio Pharma
BBIO
+$4.59M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$13.5M
2
PCVX icon
Vaxcyte
PCVX
+$8.74M
3
SLNO
Soleno Therapeutics
SLNO
+$8.25M
4
INDV icon
Indivior Pharmaceuticals
INDV
+$7.23M
5
BMY icon
Bristol-Myers Squibb
BMY
+$5.86M

Sector Composition

Rank Sector Weight
1 Healthcare 28.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TERN
51
CALL
DELISTED
Terns Pharmaceuticals
TERN
$2.61M 0.45%
64,700
-160,500
-71% -$3.71M
SLNO
52
CALL
DELISTED
Soleno Therapeutics
SLNO
$2.46M 0.42%
53,100
+3,100
+6% +$170K
IMCR icon
53
Immunocore
IMCR
$1.72B
$2.44M 0.42%
70,300
-54,084
-43% -$1.91M
OLMA icon
54
CALL
Olema Pharmaceuticals
OLMA
$1B
$2.4M 0.41%
96,100
+5,600
+6% +$99.6K
IRWD icon
55
Ironwood Pharmaceuticals
IRWD
$696M
$2.3M 0.4%
+683,611
New +$1.78M
RARE icon
56
CALL
Ultragenyx Pharmaceutical
RARE
$2.45B
$2.3M 0.4%
100,000
-50,000
-33% -$1.64M
BHVN icon
57
CALL
Biohaven
BHVN
$2.03B
$2.26M 0.39%
+200,000
New +$2.48M
CNTA
58
DELISTED
Centessa Pharmaceuticals
CNTA
$2.25M 0.39%
+90,000
New +$2.28M
REPL icon
59
Replimune Group
REPL
$941M
$2.25M 0.39%
+230,997
New +$1.96M
AQST icon
60
PUT
Aquestive Therapeutics
AQST
$463M
$2.18M 0.38%
+337,700
New +$2.1M
LLY icon
61
Eli Lilly
LLY
$1.02T
$2.15M 0.37%
+2,000
New +$1.91M
ALNY icon
62
Alnylam Pharmaceuticals
ALNY
$27.5B
$2.12M 0.37%
5,341
-4,659
-47% -$2.06M
TECX
63
CALL
Tectonic Therapeutic
TECX
$529M
$2.1M 0.36%
100,600
+600
+0.6% +$11.2K
LPCN icon
64
Lipocine
LPCN
$17.5M
$2.1M 0.36%
+260,939
New +$878K
PTGX icon
65
Protagonist Therapeutics
PTGX
$8.79B
$1.98M 0.34%
22,700
-28,485
-56% -$2.33M
TVTX icon
66
PUT
Travere Therapeutics
TVTX
$5.2B
$1.92M 0.33%
50,300
+50,000
+16,667% +$1.63M
NTLA icon
67
CALL
Intellia Therapeutics
NTLA
$1.49B
$1.91M 0.33%
212,400
-257,800
-55% -$3.55M
RLMD icon
68
Relmada Therapeutics
RLMD
$557M
$1.88M 0.32%
+389,395
New +$1.3M
CRMD icon
69
PUT
CorMedix
CRMD
$591M
$1.85M 0.32%
159,000
+59,000
+59% +$652K
VTYX
70
DELISTED
Ventyx Biosciences
VTYX
$1.81M 0.31%
200,000
+128,796
+181% +$963K
ALT icon
71
CALL
Altimmune
ALT
$552M
$1.78M 0.31%
491,800
+28,800
+6% +$126K
VNDA icon
72
CALL
Vanda Pharmaceuticals
VNDA
$307M
$1.76M 0.3%
+200,000
New +$1.1M
ANNX icon
73
Annexon
ANNX
$834M
$1.76M 0.3%
+350,000
New +$1.34M
MNKD icon
74
MannKind Corp
MNKD
$1.21B
$1.71M 0.3%
302,000
+89,525
+42% +$493K
SLS icon
75
CALL
SELLAS Life Sciences
SLS
$1.97B
$1.6M 0.28%
424,900
+24,900
+6% +$48.4K
1 2
3
4 5

Similar funds

MC
Martin & Co Knoxville, Tennessee $587M AUM 16.39% 1-Year Est. Return
PFG
Premier Financial Group Eureka, California $587M AUM 21.88% 1-Year Est. Return
FMI
Frec Markets Inc San Francisco, California $587M AUM
EGWAG
Elwood & Goetz Wealth Advisory Group Athens, Georgia $589M AUM 19.26% 1-Year Est. Return
PFG
PAX Financial Group San Antonio, Texas $586M AUM 15.84% 1-Year Est. Return
GIM
Garden Investment Management Greenwich, Connecticut $586M AUM 15.35% 1-Year Est. Return
FL
Fourthstone LLC St Louis, Missouri $590M AUM 29.58% 1-Year Est. Return
BA
Bellwether Advisors Lincoln, Nebraska $590M AUM 35.66% 1-Year Est. Return

Diadema Partners's Q4 2025 Portfolio in Review

As of Q4 2025, Diadema Partners held 201 positions worth $581M, up 48% from $391M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Diadema Partners deployed $101M of net new capital in Q4 2025, opening 71 new positions and adding to 49 existing holdings. Its largest new stake was Johnson & Johnson: 66,444 shares worth $13.8M.

By sector, the portfolio is most concentrated in Healthcare at 29% of assets, down from 37% a quarter earlier.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $13.5M trimmed.

  • Diadema Partners's largest Q4 2025 buy was Johnson & Johnson: 66,444 shares worth $13.8M.
  • Diadema Partners added most to Viking Therapeutics in Q4 2025, an estimated $5.07M increase.
  • Diadema Partners's biggest Q4 2025 reduction was Regeneron Pharmaceuticals, cutting an estimated $13.5M.
  • Diadema Partners fully exited Bristol-Myers Squibb in Q4 2025, selling an estimated $5.86M.
  • Diadema Partners's ten largest holdings make up 40% of its $581M portfolio in Q4 2025.
  • Diadema Partners opened 71 new positions and closed 56 in Q4 2025.
  • Diadema Partners's portfolio value rose 48% quarter-over-quarter to $581M.

Based on Diadema Partners's 13F filing for Q4 2025, filed 17 Feb 2026.